Providing comprehensive and timely information to our shareholders is important to us. The company has provided background information on our target diseases, the available clinical data, and our rationale for each Phase 3 study design, in the form of an investor webcast.
Daridorexant Phase 3 data published in The Lancet Neurology
Selatogrel Phase 3 initiation
In June 2021, Idorsia announced the initiation of the Phase 3 registration study “SOS-AMI” to evaluate the efficacy and safety of self-administered subcutaneous selatogrel, Idorsia’s P2Y12 receptor antagonist, in suspected acute myocardial infarction (AMI).
Clazosentan Phase 3 advancing
In June 2018, Idorsia announced that it is initiating a Phase 3 study, REACT, to investigate the efficacy and safety of clazosentan for the prevention of clinical deterioration due to vasospasm-related delayed cerebral ischemia in patients following an aneurysmal subarachnoid hemorrhage. The company also gave an update on the Japanese registration program and the establishment of Idorsia Pharmaceuticals Japan.
The information in these investor webcasts was factually accurate at the time of broadcast. These webcasts remain on the Idorsia website for historical purposes only. Idorsia assumes no responsibility to update the information to reflect subsequent developments. Readers should not rely upon the information in these presentations as current or accurate after their publication dates.